1. Reconciled Infectious Disease and Vaccines Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 5,536 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 1,149 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 2,510 / 933 | 27.10% closed-trial attrition ratio across 3,443 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 228 / 99 / 61 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 82.4% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Infectious Disease and Vaccines
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| Sanofi | Biopharma Industry | 328 | 103 | 152 | 132 |
| GSK | Biopharma Industry | 304 | 128 | 130 | 116 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Federal / Public Agency | 185 | 54 | 99 | 0 |
| University of Oxford | Academic / Institutional Sponsor | 67 | 22 | 32 | 0 |
| ModernaTX | Biopharma Industry | 62 | 14 | 42 | 0 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Academic / Institutional Sponsor | 35 | 13 | 7 | 0 |
| London School of Hygiene and Tropical Medicine | Academic / Institutional Sponsor | 34 | 5 | 20 | 0 |
| ANRS, Emerging Infectious Diseases | Federal / Public Agency | 32 | 13 | 7 | 0 |
| ViiV Healthcare | Biopharma Industry | 30 | 11 | 16 | 0 |
| Shionogi | Biopharma Industry | 29 | 9 | 15 | 8 |
| Sinovac Biotech Co | Biopharma Industry | 27 | 12 | 15 | 0 |
| Sorrento Therapeutics | Biopharma Industry | 27 | 0 | 3 | 0 |
3. Representative Multi-Center Phase II & III Infectious Disease and Vaccines Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT05905172 | Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis | Beijing Continent Pharmaceutical Co | Phase III | RECRUITING |
| NCT06075745 | Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates | National Institute of Allergy and Infectious Diseases (NIAID) | Phase II | RECRUITING |
| NCT07512596 | Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Nega | Chia Tai Tianqing Pharmaceutical Group Co | Phase II | RECRUITING |
| NCT07184827 | Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women | TCM Biotech International | Phase III | RECRUITING |
| NCT06577558 | Efficacy and Safety of SR1375 in Adult Patients With CAP | Shanghai SIMR Biotechnology Co | Phase II | RECRUITING |
| NCT07388680 | Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | Beijing Continent Pharmaceutical Co | Phase II/III | RECRUITING |
| NCT07157007 | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 | Traws Pharma | Phase II | RECRUITING |
| NCT07209761 | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Otsuka Pharmaceutical Development & Commercialization | Phase III | RECRUITING |
| NCT05639647 | Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections | Pfizer | Phase II | RECRUITING |
| NCT05026749 | Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children | University of Alabama at Birmingham | Phase III | RECRUITING |
| NCT07722741 | Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC | Geneos Therapeutics | Phase II | RECRUITING |
| NCT06866405 | A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose | Pfizer | Phase III | RECRUITING |
| NCT06998043 | Study With Phage for CF Subjects With Pseudomonas Lung Infection | BiomX | Phase II | RECRUITING |
| NCT06631287 | Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID | Wes Ely | Phase III | RECRUITING |
| NCT05832229 | Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase II | RECRUITING |
| NCT06925321 | A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. | Basilea Pharmaceutica | Phase III | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Neurology, Psychiatry, and Pain · Immunology, Rheumatology, and Dermatology, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.